The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 2067-2079

  Martins De Souza, Daniel ^a   Harris, Laura W ^a   Guest, Paul C ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; INSULIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CALCIUM HOMEOSTASIS; CITRIC ACID CYCLE; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; LIPID METABOLISM; MASS SPECTROMETRY; MITOCHONDRION; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCHIZOPHRENIA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ENERGY METABOLISM; HUMANS; LIPID METABOLISM; OXIDATIVE STRESS; PROTEOME; SCHIZOPHRENIA;

EID: 80051964408     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3459     Document Type: Review

References (92)

1. Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich ME, and Morales L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 41: 1989-2004, 2009.
2. Andreasen N, Nasrallah HA, Dunn V, Olson SC, Grove WM, Ehrhardt JC, Coffman JA, and Crossett JH. Structural abnormalities in the frontal system in schizophrenia: a magnetic resonance imaging study. Arch Gen Psychiatry 43: 136-144, 1986. (Pubitemid 16163532)
3. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, and de Baptista EA. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93: 99-108, 2007. (Pubitemid 46839067)
4. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, and Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for diseaseassociated changes. Proteomics 6: 3414-3425, 2006. (Pubitemid 43886157)
5. Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, and Klein E. Increased mitochondrial complex I activity in platelets of schizophrenia patients. Int J Neuropsychopharmacol 2: 245-253, 1999
6. Ben-Shachar D and Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59: 273-296, 2004. (Pubitemid 39752419)
7. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 116: 1383-1396, 2009.
8. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, and Mansfield BC. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 2872-2881, 2008
9. Boekema EJ and Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem 282: 1-4, 2007. (Pubitemid 47076588)
10. Butterfield DA and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009.
11. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, and Baptista T. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113: 19-26, 2009.
12. Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrania Y, Wayland MT, Li P, and Bahn S. Identification of targeted analyte clusters for studies of schizophrenia. Mol Cell Proteomics [Epub ahead of print], 2009.
13. Clark D, Dedova I, Cordwell S, and Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11: 459-470, 2006.
14. Cosgrove J and Newell TG. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47: 159-169, 1991.
15. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 365-384, 2006.
16. de la Monte SM, Longato L, Tong M, DeNucci S, and Wands JR. The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health 6: 2055-2075, 2009.
17. Delaleu N, Immervoll H, Cornelius J, and Jonsson R. Biomarker profiles in serum and saliva of experimental Sjogren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 10: R22, 2008.
18. Dietrich-Muszalska A and Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry. 10: 27-33, 2009.
19. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, and Schwartz SM. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58: 1465-1474, 2008. (Pubitemid 351705936)
20. Escobar GP and Lindsey ML. Multi-analyte profiling of postmyocardial infarction plasma samples. FASEB J 21: 746.11, 2007.
21. Fan X, Liu E, Pristach C, Goff DC, and Henderson DC. Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. Schizophr Res 86: 30-35, 2006. (Pubitemid 44234036)
22. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, and Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 32: 244-252, 2006. (Pubitemid 43670234)
23. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, and Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194: 434-438, 2009.
24. Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, Esmatjes E, Conget I, and Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 103: 110-113, 2008.
25. Fucetola R, Newcomer JW, Craft S, and Melson AK. Age-and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 88: 1-13, 1999. (Pubitemid 29494963)
26. Gattaz WF and Brunner J. Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 55: 109-113, 1996.
27. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, and Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 28: 495-501, 1990. (Pubitemid 20298440)
28. Geraud G, Arné-Bès MC, Gü ell A, and Bes A. Reversibility of hemodynamic hypofrontality in schizophrenia. J Cereb Blood Flow Metab. 7: 9-12, 1987. (Pubitemid 17018309)
29. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, Wayland MT, Umrania Y, Herberth M, Koethe D, van Beveren JM, Rothermundt M, McAllister G, Leweke FM, Steiner J, and Bahn S. Increased levels of circulating insulinrelated peptides in first-onset, antipsychotic näve schizophrenia patients. Mol Psychiatry 15: 118-119, 2010.
30. Gulidova GP and Polianskaia NP. Possible reasons for changes in energy metabolism in brain mitochondria under the influence of schizophrenic patients' serum. Zh Nevropatol Psikhiatr Im S S Korsakova 73: 110-116, 1973.
31. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, and Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 155: 56-61, 2008. (Pubitemid 350234773)
32. Gygi SP, Corthals GL, Zhang Y, Rochon Y, and Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97: 9390-9395, 2000. (Pubitemid 30650785)
33. Hamazaki K, Choi KH, and Kim HY. Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. J Psychiatry Res 2010 [Epub ahead of print].
34. Harris LJW, Swatton JE, Wengenroth M, Wayland M, Lockstone HE, Holland A, Faull RLM, Lilley KS, and Bahn S. Differences in protein profiles in schizophrenia prefrontal cortex compared to other major brain disorders. Clin Schizophrenia Relat Psychoses 1: 21-39, 2007.
35. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122: 593-624, 1999. (Pubitemid 29158770)
36. Hayes JD, Flanagan JU, and Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51-88, 2005. (Pubitemid 40261798)
37. Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, Kinderlehrer R, Haznedar MM, Shihabuddin L, and Siever LJ. Three dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 156: 1190-1199, 1999. (Pubitemid 29374878)
38. Heidema CR. Bloedsuikerbepalingen bij psyebiatrische en neurologische patienten. Dissertation, Utrecht, 1918.
39. Herberth M, Koethe D, Cheng TM, Krzyszton ND, Schoeffmann S, Guest PC, Rahmoune H, Harris LW, Kranaster L, Leweke MF, and Bahn S. Impaired glycolytic response in peripheral blood mononuclear cells of first onset antipsychotic-näve schizophrenia patients identified by proteomic profiling. Mol Psychiatry 2010. (In press); DOI: 10.1038=mp .2010.71.
40. Holt RI, Peveler RC, and Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabetes Med 21: 515-523, 2004. (Pubitemid 38746268)
41. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease, Lancet 1: 936-937, 1977.
42. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30: 193-208, 1998. (Pubitemid 28189552)
43. Howes OD and Kapur S. The dopamine hypothesis of schizophrenia: version III: the final common pathway. Schizophr Bull 35: 549-562, 2009.
44. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, Gerth CW, Gross S, Schreiber D, Lilley K, Wayland M, Oxley D, Leweke FM, and Bahn S. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry. 13: 1118-1128, 2008.
45. Jacquy J, Wilmotte J, Piraux A, and Noël G. Cerebral blood flow patterns studied by rheoencephalography in schizophrenia. Neuropsychobiology 2: 94-103, 1976.
46. Javitt DC and Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308, 1991.
47. Ji B, La Y, Gao L, Zhu H, Tian N, Zhang M, Yang Y, Zhao X, Tang R, Ma G, Zhou J, Meng J, Ma J, Zhang Z, Li H, Feng G, Wang Y, He L, and Wan C. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res 8: 3633-3641, 2009.
48. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, and Yolken RH. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder: the Stanley Neuropathology Consortium. Mol Psychiatry 5: 142-149, 2000. (Pubitemid 30229428)
49. Kanehisa M and Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000. (Pubitemid 30047706)
50. Knowles MR, Cervino S, Skynner HA, Hunt SP, de Felipe C, Salim K, Meneses-Lorente G, McAllister G, and Guest PC. Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis. Proteomics 3: 1162-1171, 2003. (Pubitemid 36929538)
51. Kooy FH. Hyperglycemia in mental disorders. Brain 17: 214-289, 1919.
52. Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, and Brown AJ. Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoproteinderived cholesterol. Pharmacogenomics J 2009. [Epub ahead of print].
53. Kuznetsova NI, ZykovIu V, and Sorokina IN. Reaction of anticerebral antibodies in the sera of patients with neuropsychic disorders to mitochondria and other fractions of brain tissue extract. Bull Eksp Biol Med. 62: 47-50, 1966.
54. La YJ, Wan CL, Zhu H, Yang YF, Chen YS, Pan YX, Feng GY, and He L. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm 114: 657-663, 2007. (Pubitemid 46664048)
55. Lee SP, Ataga KI, Zayed M, Manganello JM, Orringer EP, Phillips DR, and Parise LV. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 139: 612-620, 2007. (Pubitemid 350043807)
56. Levin Y, Schwarz E, Wang L, Leweke FM, and Bahn S. Label-free LC-MS=MS quantitative proteomics for large-scale biomarker discovery in complex samples. J Sep Sci 30: 2198-2203, 2007. (Pubitemid 47497019)
57. Liebzeit KA, Markowitz JS, and Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 11: 25-32, 2001. (Pubitemid 32162499)
58. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, and Yates JR 3rd. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17: 676-682, 1999. (Pubitemid 29316146)
59. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J, Hill MD, Robbins MJ, Benzel IM, Umrania Y, Guest PC, Levin Y, Maycox PR, and Bahn S. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res 8: 3284-3297, 2009.
60. Martins-de-Souza D. Proteomics is not only a biomarker discovery tool. Proteomics Clin Appl 3: 1136-1139, 2009.
61. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyás E, Eberlin MN, Souza GH, Marangoni S, Novello JC, Turck CW, and Dias-Neto E. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatry Res 43: 978-986, 2009.
62. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, Maccarrone G, Turck CW, and Dias-Neto E. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116: 275-289, 2009.
63. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, and Turck CW. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259: 151-163, 2009.
64. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, and Dias-Neto E. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 9: 17, 2009.
65. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, Lebar M, Falkai P, Schmitt A, and Turck CW. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers for schizophrenia. J Psychiatr Res 2010. [Epub ahead of print]; DOI: 10.1016=J.psychires.2010.04.014.
66. Martins-de-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, Turck CW, and Gattaz WF. Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry. 11: 110-120, 2010.
67. Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, Lecic-Tosevski D, and Spasic MB. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of longterm clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 [Epub ahead of print]
68. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 13: S170-S177; 2007. (Pubitemid 350231678)
69. Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, Masliah J, and Wolf C. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res 169: 91-96, 2009.
70. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, Wait R, Dunn MJ, and Cotter DR. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13: 1102-1117, 2009.
71. Pennington K, Dicker P, Dunn MJ, and Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8: 5097-5107, 2008.
72. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, and Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697, 2004. (Pubitemid 38932173)
73. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, and Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6: 141-149, 2007. (Pubitemid 46173666)
74. Radonjić NV, Knez̈ević ID, Vilimanovich U, Kravić-Stevović T, Marina LV, Nikolić T, Todorović V, Bumbas̈irević V, and Petronijević ND. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 58: 739-745, 2010.
75. Ryan MC, Collins P, and Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289, 2003. (Pubitemid 41110453)
76. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, and Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 56: 41-45, 2004. (Pubitemid 38813404)
77. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, and Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7: 4266-4277, 2008.
78. Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, and Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl 1: 1291-1305, 2007.
79. Spelman LM, Walsh PI, Sharifi N, Collins P, and Thakore JH. Impaired glucose tolerance in first-episode drug-näve patients with schizophrenia. Diabetes Med 24: 481-485, 2007. (Pubitemid 46669314)
80. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B, Brauner M, Bernstein HG, Gos T, Herberth M, Schroeter ML, Schwarz MJ, Westphal S, Bahn S, and Bogerts B. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15: 3-4, 2010.
81. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK, and CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107: 1-12, 2009.
82. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, and Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49: 522-530, 1992.
83. Trepsat. Etude des troubles psychiques dans la demence precoee. These de Paris, 1905.
84. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, and Sauerwein HP. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93: 572-577, 2008. (Pubitemid 351240833)
85. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, and Shetty KT. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164: 1557-1560, 2007. (Pubitemid 350069735)
86. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, and Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: mycoplasma genitalium. Electrophoresis 7: 1090-1994, 1995.
87. Williamson P. Hypofrontality in schizophrenia: a review of the evidence. Can J Psychiatry 32: 399-404, 1987. (Pubitemid 17137960)
88. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, Gomez-Mont F, and Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 142: 564-571, 1985. (Pubitemid 15034624)
89. Yao JK, Leonard S, and Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42: 7-17, 2000. (Pubitemid 30116755)
90. Yao JK, Reddy RD, and van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15: 287-310, 2001. (Pubitemid 32337052)
91. Yao JK and Reddy RD. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. Sci World J 2: 1922-1936, 2002.
92. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, and Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-näve patients with schizophrenia. PLoS One 5: e9508, 2010.